Search

Displaying results 1471 - 1480 of 10000 in total
  1. Drug

    Kappadione

    go.drugbank.com/drugs/DB09332
    Approved

    It has been found to have carcinogenic potential in mammalian cells as well as cytotoxic properties [L1544]. … Studies involving the active metabolite of this formulation, menadione, showed oocyte toxicity in a study of mice [L1544].

  2. Drug

    Guanabenz

    go.drugbank.com/drugs/DB00629
    ApprovedWithdrawn

    Guanabenz is an alpha-2 selective adrenergic agonist used as an antihypertensive agent.

    Synonyms: N-(2,6-DICHLOROBENZYLIDENE)-N'-AMIDINOHYDRAZINE
  3. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

    Synonyms: N-methylhyoscine bromide, N-methylscopolammonium bromide
  4. Drug

    Protein S human

    go.drugbank.com/drugs/DB13149
    ApprovedInvestigational

    It serves as a negative feedback mechanism in the coagulation cascade.

    Mixtures: OCTAPLEX POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET
  5. Drug

    Rurioctocog alfa pegol

    go.drugbank.com/drugs/DB16007
    ApprovedInvestigational

    Factor VIII is an essential protein involved in normal blood clotting; thus, a deficient level of functional factor VIII is associated with an elevated risk for excessive bleeding caused by spontaneous … It was first approved by the European Commission in January 2018.

  6. Drug

    Carbimazole

    go.drugbank.com/drugs/DB00389
    Approved

    An imidazole antithyroid agent. Carbimazole is metabolized to methimazole, which is responsible for the antithyroid activity.

  7. Drug

    Caplacizumab

    go.drugbank.com/drugs/DB06081
    ApprovedInvestigational

    Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]

  8. Drug

    Diclofenamide

    go.drugbank.com/drugs/DB01144
    Approved

    A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.

  9. Drug

    Gastric intrinsic factor

    go.drugbank.com/drugs/DB09349
    Approved

    in the small intestine. … However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias

    Mixtures: EnLyte Extra-LN
  10. Drug

    Streptococcus pneumoniae type 4 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10322
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.

    Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer Fertigspritze